In this open access publication in PLoS it is<\/p>\n
…suggest that, compared with placebo, the new-generation antidepressants do not produce clinically significant improvements in depression in patients who initially have moderate or even very severe depression, but show significant effects only in the most severely depressed patients. The findings also show that the effect for these patients seems to be due to decreased responsiveness to placebo, rather than increased responsiveness to medication. Given these results, the researchers conclude that there is little reason to prescribe new-generation antidepressant medications to any but the most severely depressed patients unless alternative treatments have been ineffective. In addition, the finding that extremely depressed patients are less responsive to placebo than less severely depressed patients but have similar responses to antidepressants is a potentially important insight into how patients with depression respond to antidepressants and placebos that should be investigated further.<\/p><\/blockquote>\n
Here is the original article.<\/a> You don’t need to be special to read it, since it is published in an Open Access journal.<\/p>\n","protected":false},"excerpt":{"rendered":"
In this open access publication in PLoS it is …suggest that, compared with placebo, the new-generation antidepressants do not produce clinically significant improvements in depression in patients who initially have moderate or even very severe depression, but show significant effects only in the most severely depressed patients. The findings also show that the effect for … Continue reading New-generation antidepressants do not produce clinically significant improvements in depression<\/span>